Finepoint Capital LP
In its 13F for Q3 2025 (holdings as of September 30, 2025, filed November 13, 2025), Finepoint Capital LP reported 5 stock positions worth $542.8 million. Its top holding was Qxo (QXO) at 78.3% of the portfolio, followed by Rxo (RXO, 20.6%) and Solid Biosciences (SLDB, 1.1%). Compared with Q2 2025, it opened 2 new positions, sold out of 2 and added to 1. The biggest buy was a new position in Rxo (RXO) and the biggest sale an exit from Liberty Media Corp.-Liberty-C (LLYVK).
- Most Recent 13F
- Q2 2026
- Location
- BOSTON, MA
- CIK
- 0001608126
- Portfolio Value
- $542.8M (Q3 2025)
- SEC Filing
- 0000904454-25-000583 ↗ filed Nov 13, 2025
Holdings Value
Holdings 5 stocks · $542.8M
| QXO Qxo Inc. | 78.29% | 22,295,615 | $425.0M | Add +5.4% |
| RXO Rxo Inc. | 20.59% | 7,266,839 | $111.8M | New |
| SLDB Solid Biosciences Inc. | 1.09% | 961,251 | $5.9M | No change |
| ANNA Aleanna Inc. | 0.02% | 27,717 | $116K | No change |
| CLDI Calidi Biotherapeutics Inc. | 0.00% | 1,042 | $2K | New |
Options reported separately and not counted above: SPY puts ($804.3M), IWM puts ($391.2M).
Other holdings (2): bonds, preferreds, convertibles and warrants · $212K (not counted above)
Total filed on the 13F, all lines: $543.0M.
Portfolio Sells Q2 2025 → Q3 2025
Portfolio Buys Q2 2025 → Q3 2025
Options Activity Q2 2025 → Q3 2025
| SPY SS SPDR S&P 500 ETF Trust-US | put | Add +2.9% | 1,207,500 | $804.3M |
| IWM iShares Russell 2000 ETF | put | Add +176.4% | 1,617,000 | $391.2M |
Calls and puts are listed by the shares they cover; their value is not part of the stock holdings above.
Notes & Other Activity Q2 2025 → Q3 2025
| LAKESHORE BIOPHARMA CO LTD | *W EXP 03/15/202 | Sold out | 489,999 | $20Kbefore exit |
Bonds, preferreds, convertibles and warrants; not part of the stock holdings or percentages above.
All Filings
| Quarter | Positions | 13F Reported Value | Top Holdings |
|---|---|---|---|
| Q2 2026 | 4 | $460.8M | QXO, RXO, ANNA, CLDI |
| Q1 2026 | 4 | $416.6M | QXO, RXO, ANNA, CLDI |
| Q4 2025 | 5 | $532.7M | QXO, RXO, SLDB, ANNA, CLDI |
| Q3 2025 | 5 | $542.8M | QXO, RXO, SLDB, ANNA, CLDI |
| Q2 2025 | 5 | $504.1M | QXO, LLYVK, SLDB, ANNA, CLDI |
| Q1 2025 | 19 | $592.5M | QXO, LBRDK, SWTX, LLYVK, ASND |
| Q4 2024 | 20 | $866.7M | QXO, LBRDK, LLYVK, ARGX, RVMD |
| Q3 2024 | 18 | $822.2M | QXO, LBRDK, RVMD, ARGX, ASND |
| Q2 2024 | 17 | $351.8M | LBRDK, RVMD, ASND, SWTX, ARGX |
| Q1 2024 | 17 | $376.0M | LBRDK, SWTX, ASND, ARVN, RVMD |